CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma, Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will present at the 2017 BIO International Convention being held June 19-22 in San Diego, CA at the San Diego Convention Center.

Event: 2017 BIO International Convention
Location: San Diego Convention Center
Date: Tuesday, June 20, 2017
Time: 11:45 AM (PT) in Company Presentation Theater 4

Cue Biopharma President and Chief Executive Officer Daniel Passeri, M.Sc., J.D., will deliver a presentation focused on the Company’s overall development strategy and the progress of its programs, including lead candidate Cue-101, which targets human papillomavirus (HPV)-associated cancers. The Company expects Cue-101 to enter the clinic in mid-2018.

About Cue Biopharma

Immune Responses, On Cue. Cue Biopharma™ is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease. CUE (Conditional, Unique Engagement) biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies. Through this platform approach, Cue Biopharma has developed a promising pipeline with its lead candidate currently approaching the clinic. Headquartered in Kendall Square, Cambridge, MA, the Company is led by a strong, experienced management team and scientific and clinical advisory board with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebio.com.